BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34624457)

  • 1. Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma.
    Das B; Jain N; Mallick B
    Gene; 2022 Jan; 808():145988. PubMed ID: 34624457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
    Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS
    Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribonucleotide reductase subunit M2 promotes proliferation and epithelial-mesenchymal transition via the JAK2/STAT3 signaling pathway in retinoblastoma.
    Yang M; Yao P; Lang X; Li X; Zhang D
    Bioengineered; 2021 Dec; 12(2):12800-12811. PubMed ID: 34895038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [SATB1 promotes the malignant of human non-Hodgkin lymphoma by activating the ribonucleotide reductase 
small subunit M2].
    Yan D; Wang W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 41(11):1155-1162. PubMed ID: 27932760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
    Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
    Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
    Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
    Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RRM2 promotes the progression of human glioblastoma.
    Li C; Zheng J; Chen S; Huang B; Li G; Feng Z; Wang J; Xu S
    J Cell Physiol; 2018 Oct; 233(10):6759-6767. PubMed ID: 29667764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.
    Zhang H; Liu X; Warden CD; Huang Y; Loera S; Xue L; Zhang S; Chu P; Zheng S; Yen Y
    BMC Cancer; 2014 Sep; 14():664. PubMed ID: 25213022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
    Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
    Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
    Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
    Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribonucleotide reductase M2 subunit silencing suppresses tumorigenesis in pancreatic cancer via inactivation of PI3K/AKT/mTOR pathway.
    Shan J; Wang Z; Mo Q; Long J; Fan Y; Cheng L; Zhang T; Liu X; Wang X
    Pancreatology; 2022 Apr; 22(3):401-413. PubMed ID: 35300916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
    Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
    Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy.
    Li J; Pang J; Liu Y; Zhang J; Zhang C; Shen G; Song L
    Oncol Rep; 2018 Jul; 40(1):355-360. PubMed ID: 29749541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.
    Lee B; Ha SY; Song DH; Lee HW; Cho SY; Park CK
    Gut Liver; 2014 Nov; 8(6):662-8. PubMed ID: 25368754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
    Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K
    Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
    Morikawa T; Hino R; Uozaki H; Maeda D; Ushiku T; Shinozaki A; Sakatani T; Fukayama M
    Hum Pathol; 2010 Dec; 41(12):1742-8. PubMed ID: 20825972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RRM2 is a potential prognostic biomarker with functional significance in glioma.
    Sun H; Yang B; Zhang H; Song J; Zhang Y; Xing J; Yang Z; Wei C; Xu T; Yu Z; Xu Z; Hou M; Ji M; Zhang Y
    Int J Biol Sci; 2019; 15(3):533-543. PubMed ID: 30745840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
    Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.
    Su YF; Wu TF; Ko JL; Tsai HT; Tee YT; Chien MH; Chou CH; Lin WL; Low HY; Chou MY; Yang SF; Wang PH
    PLoS One; 2014; 9(3):e91644. PubMed ID: 24637958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
    Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R
    Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.